Kyverna Therapeutics (NASDAQ:KYTX) Price Target Cut to $6.00 by Analysts at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX) had its target price lowered by HC Wainwright from $7.00 to $6.00 in a research report report published on Wednesday,Benzinga reports. The firm currently has a neutral rating on the stock. HC Wainwright also issued estimates for Kyverna Therapeutics’ FY2024 earnings at ($3.14) EPS and Q4 2025 earnings at ($0.77) EPS.

A number of other equities analysts have also recently weighed in on the company. RODMAN&RENSHAW raised Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. Wells Fargo & Company cut their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They issued a “buy” rating and a $13.00 price objective for the company. JPMorgan Chase & Co. cut their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Finally, Rodman & Renshaw began coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $16.00 target price for the company. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Kyverna Therapeutics has a consensus rating of “Buy” and an average target price of $25.71.

Kyverna Therapeutics Stock Performance

KYTX opened at $4.39 on Wednesday. The business has a 50 day moving average price of $5.17 and a two-hundred day moving average price of $8.14. Kyverna Therapeutics has a 1-year low of $3.92 and a 1-year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter. Sell-side analysts anticipate that Kyverna Therapeutics will post -3.29 EPS for the current year.

Institutional Investors Weigh In On Kyverna Therapeutics

Several hedge funds have recently made changes to their positions in KYTX. Barclays PLC increased its position in shares of Kyverna Therapeutics by 21.5% during the third quarter. Barclays PLC now owns 70,167 shares of the company’s stock valued at $343,000 after purchasing an additional 12,418 shares during the period. Geode Capital Management LLC increased its holdings in Kyverna Therapeutics by 19.0% in the 3rd quarter. Geode Capital Management LLC now owns 443,312 shares of the company’s stock valued at $2,168,000 after buying an additional 70,714 shares during the period. Jane Street Group LLC raised its stake in shares of Kyverna Therapeutics by 78.3% in the 3rd quarter. Jane Street Group LLC now owns 39,193 shares of the company’s stock valued at $192,000 after buying an additional 17,215 shares in the last quarter. Sphera Funds Management LTD. lifted its holdings in shares of Kyverna Therapeutics by 5.3% during the 3rd quarter. Sphera Funds Management LTD. now owns 248,651 shares of the company’s stock worth $1,216,000 after acquiring an additional 12,622 shares during the period. Finally, State Street Corp boosted its position in shares of Kyverna Therapeutics by 3.2% during the 3rd quarter. State Street Corp now owns 326,192 shares of the company’s stock valued at $1,595,000 after acquiring an additional 10,244 shares in the last quarter. Institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.